Table 1.
Characteristics of critical care patients with SARS-CoV2 infection.
| Acute n = 15 |
MIS-C n = 21 |
Neurological n = 11 |
p value | |
|---|---|---|---|---|
| Age, months | 12 (6; 144) | 84 (32.5; 120) | 60 (12; 156) | 0.51 |
| Sex, male | 7 (46.7%) | 15 (71.4%) | 8 (72.7%) | 0.25 |
| Admission, referred | 11 (73.3%) | 13 (61.9%) | 7 (63.6%) | 0.79 |
| Out-of-city transfer | 3 (20%) | 2 (9.5%) | 2 (18.2%) | 0.66 |
| Comorbidities | 12 (80%) | 1 (4.8%) | 2 (18.2%) | <0.01 |
| Kawasaki | ||||
| Complete | – | 7 (33.3%) | – | – |
| Atypical | 6 (28.6%) | 1 (9.1%) | ||
| PaO2/FiO2 < 100 | 7 (46.7%) | – | 1 (9.1%) | 0.17 |
| LOS PICU, days | 6 (3; 15) | 6 (4.5; 10) | 9 (7; 12) | 0.35 |
| LOMV, days, n = 15 | 7 (3; 15) | 7 (4.25; 10.5) | 6.5 (3.5; 8.5) | 0.47 |
| Mortality | 4 (26.7%) | 1 (4.8%) | 5 (45.5%) | 0.02 |
| Steroids | 11 (73.3%) | 8 (38.1%) | 9 (81.8%) | 0.03 |
| Vasoactive med. | 6 (40%) | 6 (28.6%) | 7 (63.6%) | 0.17 |
| COVID directed therapy | 4 (26.7%) | 6 (28.6%) | 4 (36.4%) | 0.84 |
| Anticoagulation | ||||
| ASA | – | 9 (42.9%) | – | <0.01 |
| ASA + LMWH | – | 6 (28.6%) | – | |
| LMWH | 2 (13.3%) | 2 (9.5%) | 4 (36.4%) | |
| IVIG | – | 15 (71.4%) | 1 (9.1%) | – |
Continuous variables expressed in median and interquartile ranges in parenthesis. Analysis: continuous variables Mann–Whitney U test; categorical Fisher’s exact test. LOS length of stay, LOMV length of mechanical ventilation, LMWH low-molecular weight heparin.